News By Tag
News By Location
Systagenix wins 2012 Award for Innovation and Technology for WOUNDCHEK™ Protease Status
Systagenix wound management scoops innovation and technology award for WoundChek Protease Status - the world's first point-of-care diagnostic test for wounds
The awards have been created to celebrate and reward business achievement, highlighting the best in business across a region that houses offices and headquarters of over 450 international businesses, including Pfizer, Novo Nordisk, PWC, BA, Virgin, and Deloitte.
Ernest Waaser, Systagenix CEO, said: “Within our business environment, Systagenix has set a very clear vision: to develop and market advanced diagnostic and therapeutic systems that enable clinicians to heal every wound predictably and cost effectively. Bringing WOUNDCHEK Protease Status to the market is a huge achievement for Systagenix, and a long awaited innovation milestone in the wound care field, where chronic wounds may not heal for months or even years and where diagnostics has notoriously lacked. Winning the Gatwick Diamond Business Awards for Innovation and Technology helps us celebrate our revolutionary launch and our contribution to the world of wound care”.
Established in 2008, following the acquisition of Johnson & Johnson’s advanced wound care business, Systagenix supplies over 20 million advanced wound dressings per month into over 100 countries worldwide. The company has just launched the world’s first rapid, point of care diagnostic test developed specifically for chronic wounds, WOUNDCHEK™ Protease Status, which has the potential to revolutionise wound care by enabling early, targeted intervention and cost effective use of advanced therapies designed to modulate protease activity. The global headquarter is based in Gatwick, City Place.
Information on Systagenix wound care can be found at http://www.systagenix.com.